Immunogenicity of pneumococcal vaccine in renal transplant recipients - Three year follow-up of a randomized trial

American Journal of Transplantation

Volumn 7, Issue 3, 2007, Pages 633-638

  Kumar, D ^a   Welsh, B ^a   Siegal, D ^a   Chen, M Hong ^a   Humar, A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; VACCINATION;

EID: 33847701746     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01668.x     Document Type: Article

References (21)

1. Linnemann CC Jr, First MR. Risk of pneumococcal infections in renal transplant patients. JAMA 1979; 241: 2619-2621.
2. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46: 1-24.
3. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004; 4(s10): 160-163.
4. Hausdorff W, Bryant J, Paradiso P, Siber G. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use. Part I. Clin Infect Dis 2000; 30: 100-121.
5. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19(3): 187-195.
6. Feikin DR, Elie CM, Goetz MB et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20(3-4): 545-553.
7. Shelly MA, Jacoby H, Riley GJ, Graves BT, Pichichero M, Treanor JH. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997; 65: 1242-1247.
8. Vernacchio L, Romero-Steiner S, Martinez JE et al. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis 2000; 181: 1162-1166.
9. Chan CY, Molrine DC, George S et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173: 256-258.
10. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187(10): 1639-1645.
11. Linnemann CC, First MR, Schiffman G. Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Intern Med 1981; 141: 1637-1640.
12. Linnemann CC, First MR, Schiffman G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med 1986; 146(8): 1554-1556.
13. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999; 18: 543-551.
14. Wernette CM, Frasch CE, Madore D et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003; 10(4): 515-519.
15. World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series No. 927, 2005.
16. Hostetter MK. Opsonic and nonopsonic interactions of C3 with Streptococcus pneumoniae. In: Tomasz A, ed. Streptococcus pneumoniae. New York: Mary Ann Liebert, Inc.; 2000: 309-313.
17. Rubins J, Alter M, Loch H, Janoff E. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999; 67: 5979-5984.
18. McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000; 181(2): 757-760.
19. Blumberg EG, Brozena SC, Stutman P,Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001; 32(2): 307-310.
20. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997; 176(4): 1100-1104.
21. Martinez JE, Romero-Steiner S, Pilishvili T et al. A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. Clin Diag Lab Immunol 1999; 6(4): 581-586.